Peptide receptor radionuclide therapyfor neuroendocrine tumours Peptide Receptor Radionuclide Therapy (PRRT) represents a significant advancement in the treatment of neuroendocrine tumors (NETs)PRRT | UCSF Center for Neuroendocrine Tumors. This specialized form of molecular targeted therapy utilizes radiolabeled peptides to specifically target tumor cells that express certain receptors, such as somatostatin receptors.Peptide receptor radionuclide therapy(PRRT) is a type of radionuclide therapy, using a radiopharmaceutical thattargets peptide receptors to deliver localised... By delivering localized radiation directly to these cancer cells, PRRT aims to slow or halt tumor growth and induce cell death, offering a crucial treatment option for patients with advanced, metastatic, or inoperable NETs2024年8月11日—Peptide Receptor Radionuclide Therapyutilises radiopharmaceuticals to target somatostatin receptor-expressing tumours, improving treatment .... The therapy has become a mainstay in managing these complex conditions, providing a more precise approach compared to traditional systemic treatments.
PRRT works by attaching a radioactive isotope to a peptide that has a high affinity for specific receptors found on the surface of neuroendocrine tumor cells. These peptides, often somatostatin analogs, act like keys that fit into the locks (receptors) on the cancer cellsPeptide receptor radionuclide therapy. Once the radiolabeled peptide binds to the receptor, it is internalized by the tumor cell, delivering a targeted dose of radiation. This mechanism ensures that the radioactive payload is concentrated within the tumor, minimizing damage to surrounding healthy tissues. The most commonly used radionuclide in PRRT is Lutetium-177 (Lu-177), often in combination with DOTATATE, a peptide that targets somatostatin receptors.作者：J Hofland·2022·被引用次数：48—First-linePRRTwith177Lu-DOTATATE and combinations of thistherapywith cytotoxic drugs are currently under investigation. New radiolabeled somatostatin ...
The primary indication for Peptide Receptor Radionuclide Therapy is for neuroendocrine tumors that express somatostatin receptorsPeptide receptor radionuclide therapy: an overview. This includes many gastroenteropancreatic (GEP) NETs, as well as NETs originating from other sites. PRRT has demonstrated considerable success in controlling the progression of these tumors, leading to improved survival rates and quality of life for many patients.peptide-receptor-radionuclide-therapy Its effectiveness is particularly noted in cases where tumors are locally advanced, metastatic, or have become resistant to other forms of treatment. The FDA-approved status of PRRT underscores its established role in the systemic treatment of neuroendocrine tumors.Peptide Receptor Radionuclide Therapy
The administration of PRRT typically involves a series of treatment cycles, often four in total, with intervals between each cyclePeptide Receptor RadionuclideTherapy (PRRT).Peptide Receptor Radionuclide Therapy(PRRT) is a treatment for neuroendocrine cancer. It involves four cycles .... Patients are usually admitted to the hospital for the duration of each treatment, with hospital stays commonly ranging from two to five days. Before the infusion of the radiopharmaceutical, patients often receive an amino acid solutionPeptide receptor radionuclide therapy. This solution helps to protect the kidneys from absorbing excessive amounts of radioactivity and prevents unintended uptake in healthy organs. The actual infusion of the radiolabeled peptide is administered intravenously.An amino acid solution is administered approximately 2 hours before the start oftherapyto protect the kidneys and prevent excessive uptake of the radioactive ... Close monitoring of the patient's response and potential side effects is a critical part of the treatment process.Fact Sheet: What is Peptide Receptor Radionuclide Therapy (PRRT)?
While PRRT is designed to be targeted, it can still lead to side effects, as with any radiation therapy. Common side effects may include fatigue, nausea, vomiting, and changes in blood countsPeptide Receptor Radionuclide Therapy. Effects on the kidneys and liver are also monitored closely due to the potential for radiation exposure to these organs. However, the protective measures, such as the amino acid solution, significantly help in mitigating kidney toxicity. Other side effects can include temporary hair loss and, in some cases, myelosuppression作者：MN Becx·2022·被引用次数：55—Peptide receptor radionuclide therapy(PRRT) is one of the treatment options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine .... Managing these side effects often involves supportive care, dose adjustments, and careful monitoring by the medical team.
The field of Peptide Receptor Radionuclide Therapy is continually evolving.Peptide Receptor Radionuclide Therapy (PRRT) Research is ongoing to explore new radionuclides, targeting peptides, and combinations of PRRT with other therapeutic modalities, such as chemotherapy or immunotherapy. Developments in alpha-particle therapies, which offer a different type of targeted radiation, are also showing promise. These advancements aim to further enhance the efficacy of PRRT, broaden its applicability to a wider range of tumors, and potentially improve patient outcomes even further. The exploration of dosimetry, which precisely measures radiation absorbed by tumors and organs, is also becoming increasingly important in optimizing treatment strategies.
Join the newsletter to receive news, updates, new products and freebies in your inbox.